Clinical Trial Update: A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies

View source ↗

Summary

This document presents a pooled analysis of belimumab (HGS1006) from the BLISS-52 and BLISS-76 trials in lupus erythematosus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Discoid Lupus Erythematosus

Drugs mentioned

• BENLYSTA (belimumab)

Snippet

Sponsor: Human Genome Sciences Inc., a GSK Company | Conditions: Lupus Erythematosus, Discoid | Status: COMPLETED